A Biomarker Development Trial of Satraplatin in Patients With mCRPC

February 1, 2014
William K. Oh, MD

William K. Oh, MD, professor of medicine, hematology and medical oncology, urology, The Mount Sinai Hospital, discusses a biomarker development trial of satraplatin in patients with metastatic castrate-resistant prostate cancer.

Clinical Pearls

William K. Oh, MD, professor of medicine, hematology and medical oncology, urology, The Mount Sinai Hospital, discusses a biomarker development trial of satraplatin in patients with metastatic castrate-resistant prostate cancer (mCRPC).

  • Satraplatin is a next-generation chemotherapy drug that will not move forward in development
  • It is known that there is a subset of patients with advanced CRPC that respond to platinum chemotherapy
  • Blood- and tissue-based biomarkers are in development to predict the subset of patients that will respond

<<<

Back to the GU 2014 conference page